Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American migraine prevalence and prevention (AMPP) study

Starr Holland, Kristina M. Fanning, Daniel Serrano, Dawn C. Buse, Michael L. Reed, Richard B. Lipton

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Persons with migraine use acute medications to manage headache pain and associated symptoms. Several studies have reported reasons why patients select specific medications; however, little is known about why patients discontinue acute medications. This study assesses reasons for discontinuation of two commonly used classes of medication - triptans and opioids. Methods This study uses data from the 2008 and 2009 AMPP surveys. Eligible subjects had episodic migraine in both 2008 and 2009 and provided data on acute treatment use in both years. The AMPP survey also assessed reasons for discontinuing migraine medications. Results Of 3,334 eligible migraineurs, 714 triptan users in 2008, 247 (34.6%) had discontinued triptans by 2009. In 2008 there were 417 opioid users, of whom 246 (59.0%) had discontinued the drug by the 2009 survey. Ordinal regression comparing the pattern of headache-related disability (MIDAS scores) revealed a decrease in headache-related disability among triptan discontinuers (21.4% moderate to severe disability) compared to opioid discontinuers (33.0% moderate to severe disability [p =.004]). Triptan discontinuers were 48% less likely to discontinue because of pain recurrence than those discontinuing opioids (p =.006), 51% less likely to discontinue due to chest pain (p =.018), and 57% less likely to discontinue due to neck pain (p =.004) compared to opioid discontinuers. Triptan discontinuers were 47% less likely to discontinue headache medication because of concern about interactions with other medications (p =.013) and 42% less likely due to concern about effects to the stomach compared to opioid users (p =.029). No differences in reasons for discontinuation were noted for efficacy of pain relief or side effects. Discussion This study shows that opioid use is associated with an increased risk of medication discontinuation compared to triptans. Reasons for medication discontinuation included return of migraine pain, concerns regarding drug interactions, and stomach upset, among others. Physicians managing patients using opioids may need to frequently assess the patient's risk of discontinuing their treatment plan, or physicians may need to be proactive and modify the treatment plan to better suite the patient's needs, which may change over time. Further studies are warranted that evaluate rates and reasons of discontinuation of other classes of acute migraine medications.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalJournal of the Neurological Sciences
Volume326
Issue number1-2
DOIs
StatePublished - 2013

Fingerprint

Tryptamines
Migraine Disorders
Opioid Analgesics
Cross-Sectional Studies
Headache
Pain
Stomach
Physicians
Neck Pain
Chest Pain
Drug Interactions
Therapeutics
Recurrence

Keywords

  • Adherence
  • Episodic migraine
  • Medication discontinuation
  • Opioid
  • Scute migraine medication
  • Triptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rates and reasons for discontinuation of triptans and opioids in episodic migraine : Results from the American migraine prevalence and prevention (AMPP) study. / Holland, Starr; Fanning, Kristina M.; Serrano, Daniel; Buse, Dawn C.; Reed, Michael L.; Lipton, Richard B.

In: Journal of the Neurological Sciences, Vol. 326, No. 1-2, 2013, p. 10-17.

Research output: Contribution to journalArticle

@article{5fc0d21fff514d85bb37059f55bd9331,
title = "Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American migraine prevalence and prevention (AMPP) study",
abstract = "Background: Persons with migraine use acute medications to manage headache pain and associated symptoms. Several studies have reported reasons why patients select specific medications; however, little is known about why patients discontinue acute medications. This study assesses reasons for discontinuation of two commonly used classes of medication - triptans and opioids. Methods This study uses data from the 2008 and 2009 AMPP surveys. Eligible subjects had episodic migraine in both 2008 and 2009 and provided data on acute treatment use in both years. The AMPP survey also assessed reasons for discontinuing migraine medications. Results Of 3,334 eligible migraineurs, 714 triptan users in 2008, 247 (34.6{\%}) had discontinued triptans by 2009. In 2008 there were 417 opioid users, of whom 246 (59.0{\%}) had discontinued the drug by the 2009 survey. Ordinal regression comparing the pattern of headache-related disability (MIDAS scores) revealed a decrease in headache-related disability among triptan discontinuers (21.4{\%} moderate to severe disability) compared to opioid discontinuers (33.0{\%} moderate to severe disability [p =.004]). Triptan discontinuers were 48{\%} less likely to discontinue because of pain recurrence than those discontinuing opioids (p =.006), 51{\%} less likely to discontinue due to chest pain (p =.018), and 57{\%} less likely to discontinue due to neck pain (p =.004) compared to opioid discontinuers. Triptan discontinuers were 47{\%} less likely to discontinue headache medication because of concern about interactions with other medications (p =.013) and 42{\%} less likely due to concern about effects to the stomach compared to opioid users (p =.029). No differences in reasons for discontinuation were noted for efficacy of pain relief or side effects. Discussion This study shows that opioid use is associated with an increased risk of medication discontinuation compared to triptans. Reasons for medication discontinuation included return of migraine pain, concerns regarding drug interactions, and stomach upset, among others. Physicians managing patients using opioids may need to frequently assess the patient's risk of discontinuing their treatment plan, or physicians may need to be proactive and modify the treatment plan to better suite the patient's needs, which may change over time. Further studies are warranted that evaluate rates and reasons of discontinuation of other classes of acute migraine medications.",
keywords = "Adherence, Episodic migraine, Medication discontinuation, Opioid, Scute migraine medication, Triptan",
author = "Starr Holland and Fanning, {Kristina M.} and Daniel Serrano and Buse, {Dawn C.} and Reed, {Michael L.} and Lipton, {Richard B.}",
year = "2013",
doi = "10.1016/j.jns.2012.12.020",
language = "English (US)",
volume = "326",
pages = "10--17",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Rates and reasons for discontinuation of triptans and opioids in episodic migraine

T2 - Results from the American migraine prevalence and prevention (AMPP) study

AU - Holland, Starr

AU - Fanning, Kristina M.

AU - Serrano, Daniel

AU - Buse, Dawn C.

AU - Reed, Michael L.

AU - Lipton, Richard B.

PY - 2013

Y1 - 2013

N2 - Background: Persons with migraine use acute medications to manage headache pain and associated symptoms. Several studies have reported reasons why patients select specific medications; however, little is known about why patients discontinue acute medications. This study assesses reasons for discontinuation of two commonly used classes of medication - triptans and opioids. Methods This study uses data from the 2008 and 2009 AMPP surveys. Eligible subjects had episodic migraine in both 2008 and 2009 and provided data on acute treatment use in both years. The AMPP survey also assessed reasons for discontinuing migraine medications. Results Of 3,334 eligible migraineurs, 714 triptan users in 2008, 247 (34.6%) had discontinued triptans by 2009. In 2008 there were 417 opioid users, of whom 246 (59.0%) had discontinued the drug by the 2009 survey. Ordinal regression comparing the pattern of headache-related disability (MIDAS scores) revealed a decrease in headache-related disability among triptan discontinuers (21.4% moderate to severe disability) compared to opioid discontinuers (33.0% moderate to severe disability [p =.004]). Triptan discontinuers were 48% less likely to discontinue because of pain recurrence than those discontinuing opioids (p =.006), 51% less likely to discontinue due to chest pain (p =.018), and 57% less likely to discontinue due to neck pain (p =.004) compared to opioid discontinuers. Triptan discontinuers were 47% less likely to discontinue headache medication because of concern about interactions with other medications (p =.013) and 42% less likely due to concern about effects to the stomach compared to opioid users (p =.029). No differences in reasons for discontinuation were noted for efficacy of pain relief or side effects. Discussion This study shows that opioid use is associated with an increased risk of medication discontinuation compared to triptans. Reasons for medication discontinuation included return of migraine pain, concerns regarding drug interactions, and stomach upset, among others. Physicians managing patients using opioids may need to frequently assess the patient's risk of discontinuing their treatment plan, or physicians may need to be proactive and modify the treatment plan to better suite the patient's needs, which may change over time. Further studies are warranted that evaluate rates and reasons of discontinuation of other classes of acute migraine medications.

AB - Background: Persons with migraine use acute medications to manage headache pain and associated symptoms. Several studies have reported reasons why patients select specific medications; however, little is known about why patients discontinue acute medications. This study assesses reasons for discontinuation of two commonly used classes of medication - triptans and opioids. Methods This study uses data from the 2008 and 2009 AMPP surveys. Eligible subjects had episodic migraine in both 2008 and 2009 and provided data on acute treatment use in both years. The AMPP survey also assessed reasons for discontinuing migraine medications. Results Of 3,334 eligible migraineurs, 714 triptan users in 2008, 247 (34.6%) had discontinued triptans by 2009. In 2008 there were 417 opioid users, of whom 246 (59.0%) had discontinued the drug by the 2009 survey. Ordinal regression comparing the pattern of headache-related disability (MIDAS scores) revealed a decrease in headache-related disability among triptan discontinuers (21.4% moderate to severe disability) compared to opioid discontinuers (33.0% moderate to severe disability [p =.004]). Triptan discontinuers were 48% less likely to discontinue because of pain recurrence than those discontinuing opioids (p =.006), 51% less likely to discontinue due to chest pain (p =.018), and 57% less likely to discontinue due to neck pain (p =.004) compared to opioid discontinuers. Triptan discontinuers were 47% less likely to discontinue headache medication because of concern about interactions with other medications (p =.013) and 42% less likely due to concern about effects to the stomach compared to opioid users (p =.029). No differences in reasons for discontinuation were noted for efficacy of pain relief or side effects. Discussion This study shows that opioid use is associated with an increased risk of medication discontinuation compared to triptans. Reasons for medication discontinuation included return of migraine pain, concerns regarding drug interactions, and stomach upset, among others. Physicians managing patients using opioids may need to frequently assess the patient's risk of discontinuing their treatment plan, or physicians may need to be proactive and modify the treatment plan to better suite the patient's needs, which may change over time. Further studies are warranted that evaluate rates and reasons of discontinuation of other classes of acute migraine medications.

KW - Adherence

KW - Episodic migraine

KW - Medication discontinuation

KW - Opioid

KW - Scute migraine medication

KW - Triptan

UR - http://www.scopus.com/inward/record.url?scp=84875469589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875469589&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2012.12.020

DO - 10.1016/j.jns.2012.12.020

M3 - Article

C2 - 23394974

AN - SCOPUS:84875469589

VL - 326

SP - 10

EP - 17

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -